Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 93

Results For "IMI"

4727 News Found

KIMS Hospital Bengaluru commences operations of new hospital in Bengaluru
Hospitals | September 17, 2025

KIMS Hospital Bengaluru commences operations of new hospital in Bengaluru

The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,


FDA approves Lupin’s Lenalidomide capsules
Drug Approval | September 17, 2025

FDA approves Lupin’s Lenalidomide capsules

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma


CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR
Healthcare | September 16, 2025

CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR

The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness


Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
News | September 16, 2025

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke


Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav
News | September 16, 2025

Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav

The inspection was carried out between May 26, 2025 and May 31, 2025


Syensqo introduces medical-grade Amodel PPA for medical devicess
Medical Device | September 16, 2025

Syensqo introduces medical-grade Amodel PPA for medical devicess

A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies


FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers
Drug Approval | September 16, 2025

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo


Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy
Clinical Trials | September 16, 2025

Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program


Rona submits IND for GalNAc-conjugated siRNA targeting obesity
Drug Approval | September 16, 2025

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options


Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Clinical Trials | September 16, 2025

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity